- Email: [email protected]
Polymers for mitochondrial DNA scavenging from blood
Abstracts / New Biotechnology 33S (2016) S1–S213
perspectives of microbial systems to use hitherto untapped will be provided. http://dx.doi.org/10.1016/j.nbt.2016.06.783
O4-2 Biocatalytic degradation of synthetic polymers: pushing the limits of performance of polyester hydrolases Wolfgang Zimmermann Microbial polyester hydrolases are promising biocatalysts for the modification and degradation of synthetic polymers such as poly(ethylene terephthalate) (PET) and polyester-type polyurethanes. These enzymes are playing a growing role in polymer processing with recent progress demonstrated in the biocatalytic functionalization of polymers with applications in textile or electronic industries and the enzymatic hydrolysis of postconsumer plastic waste in novel environmentally benign recycling processes. Features of the enzymes influencing their hydrolytic activity, substrate specificity, and thermostability will be discussed and strategies for enhancing their performance in polymer processing by enzyme and bioprocess engineering will be presented. http://dx.doi.org/10.1016/j.nbt.2016.06.784
O4-3 Polymers for mitochondrial DNA scavenging from blood Matthew Simmonte ∗ , Mark Bradley University of Edinburgh, United Kingdom Modern healthcare has been revolutionised by polymer-based materials. Their biocompatibility and tailorability have allowed their integration into a diverse range of settings; however, developing novel biomaterials for complex or niche applications through traditional approaches is difficult and time consuming. Highthroughput polymer microarrays allow for the identification of biomedically relevant interactions in a time and cost-effective manner. From the many successes that this methodology has elucidated, we present here the development of a blood-compatible substrate for the scavenge of immunogenic mitochondrial DNA (mtDNA) as a means of regulating sterile inflammation. 380 polyacrylates, acrylamides, and urethanes were contact printed as a polymer microarray and evaluated against whole blood of which 214 polymer candidates were deemed non-blood reactive, based on the absence of leukocyte, erythrocyte, and platelet binding. These polymers were reproduced in a revised 2nd generation microarray focused on mtDNA scavenging. In the presence of mtDNA from HepG2 cells, six polymers were selected for their robust PicoGreen signal, which was used to stain mtDNA. In scaleup experiments with these six polymers, polyacrylate 434 showed a remarkable capacity to scavenge mtDNA from solution with 74% and 99% of total mtDNA being scavenged after 1 and 24 hours, respectively. Together these results provide the basis of a novel anti-inflammatory hemopurification device using substrates identified by polymer microarray. http://dx.doi.org/10.1016/j.nbt.2016.06.785
S17
O4-4 Designing protein nanoparticles to hit cancer cells Esther Vazquez 1,∗ , Ugutz Unzueta 2 , Virtudes Cespedes 3 , Mireia Pesarrodona 2 , Fabian Rueda 3 , Zhikun Xu 4 , Alejandro Sanchez-Chardi 5 , Oscar Conchillo-Solé 4 , Naroa Serna 4 , Laura Sánchez 4 , Xavier Daura 4 , Monica Roldan 4 , Neus Ferrer-Miralles 4 , Ramon Mangues 6 , Antonio Villaverde 4 1
Autonomous University of Barcelona, Spain Biomedical Research Institute Sant Pau (IIB-SantPau), Spain 3 Hospital de la Santa Creu i Sant Pau, Spain 4 Universitat Autònoma de Barcelona, Spain 5 Bellaterra, Spain 6 Universitat Autónoma de Barcelona, Spain 2
Targeted therapy represents one of the major challenges in Nanomedicine, with less than 5% of the antibody-targeted vehicles reaching target cells in most cases. In this regard, apart from displaying a specific ligand, it is critical to control biodistribution upon systemic administration by using vehicles of a suitable size and biological nature to avoid being captured in undesired organs, thus increasing their circulating times. In this context, we have developed a recombinant platform for the design of protein carriers that self-assemble as nanostructured materials. These proteins consist of different domains designed to target the cargo drug to a specific cell type and subcellular compartment, but also of architectural domains that promote self-assembling as nanoparticles of regular size. The combination of these features makes our de novo-designed vehicles fully biocompatible biomaterials with controllable physical and functional properties, stable in the bloodstream. We have developed nanoparticles targeted to specific cell types in different cancer models through recognition of cell surface markers and subsequent internalization, which confers specificity to the cargo antitumor drug. Such targeting minimizes drug side effects and increases its effectiveness in vivo. As an example, we describe the engineering of protein-only nanoparticles targeted to metastatic colorectal cancer. http://dx.doi.org/10.1016/j.nbt.2016.06.786
O4-5 Withdrawn
http://dx.doi.org/10.1016/j.nbt.2016.06.787
O4-6 Bacterial nanocellulose – A biotechnological product for biomedical applications Karolina Ludwicka ∗ , Przemysław Rytczak, Marek Kołodziejczyk, Edyta Gendaszewska-Darmach, Michał Chrzanowski, Katarzyna ˛ Kubiak, Marzena Jedrzejczak-Krzepkowska, Stanisław Bielecki Lodz University of Technology, Poland The interest in bacterial nanocellulose (BNC) application in medicine and tissues reconstruction has grown rapidly in the past decade. Different types of cellulosic implants are being analysed in accordance with the required properties. Native BNC, known as an excellent wet wound dressing, was developed at the Institute of Technical Biochemistry and already successfully applied in
perspectives of microbial systems to use hitherto untapped will be provided. http://dx.doi.org/10.1016/j.nbt.2016.06.783
O4-2 Biocatalytic degradation of synthetic polymers: pushing the limits of performance of polyester hydrolases Wolfgang Zimmermann Microbial polyester hydrolases are promising biocatalysts for the modification and degradation of synthetic polymers such as poly(ethylene terephthalate) (PET) and polyester-type polyurethanes. These enzymes are playing a growing role in polymer processing with recent progress demonstrated in the biocatalytic functionalization of polymers with applications in textile or electronic industries and the enzymatic hydrolysis of postconsumer plastic waste in novel environmentally benign recycling processes. Features of the enzymes influencing their hydrolytic activity, substrate specificity, and thermostability will be discussed and strategies for enhancing their performance in polymer processing by enzyme and bioprocess engineering will be presented. http://dx.doi.org/10.1016/j.nbt.2016.06.784
O4-3 Polymers for mitochondrial DNA scavenging from blood Matthew Simmonte ∗ , Mark Bradley University of Edinburgh, United Kingdom Modern healthcare has been revolutionised by polymer-based materials. Their biocompatibility and tailorability have allowed their integration into a diverse range of settings; however, developing novel biomaterials for complex or niche applications through traditional approaches is difficult and time consuming. Highthroughput polymer microarrays allow for the identification of biomedically relevant interactions in a time and cost-effective manner. From the many successes that this methodology has elucidated, we present here the development of a blood-compatible substrate for the scavenge of immunogenic mitochondrial DNA (mtDNA) as a means of regulating sterile inflammation. 380 polyacrylates, acrylamides, and urethanes were contact printed as a polymer microarray and evaluated against whole blood of which 214 polymer candidates were deemed non-blood reactive, based on the absence of leukocyte, erythrocyte, and platelet binding. These polymers were reproduced in a revised 2nd generation microarray focused on mtDNA scavenging. In the presence of mtDNA from HepG2 cells, six polymers were selected for their robust PicoGreen signal, which was used to stain mtDNA. In scaleup experiments with these six polymers, polyacrylate 434 showed a remarkable capacity to scavenge mtDNA from solution with 74% and 99% of total mtDNA being scavenged after 1 and 24 hours, respectively. Together these results provide the basis of a novel anti-inflammatory hemopurification device using substrates identified by polymer microarray. http://dx.doi.org/10.1016/j.nbt.2016.06.785
S17
O4-4 Designing protein nanoparticles to hit cancer cells Esther Vazquez 1,∗ , Ugutz Unzueta 2 , Virtudes Cespedes 3 , Mireia Pesarrodona 2 , Fabian Rueda 3 , Zhikun Xu 4 , Alejandro Sanchez-Chardi 5 , Oscar Conchillo-Solé 4 , Naroa Serna 4 , Laura Sánchez 4 , Xavier Daura 4 , Monica Roldan 4 , Neus Ferrer-Miralles 4 , Ramon Mangues 6 , Antonio Villaverde 4 1
Autonomous University of Barcelona, Spain Biomedical Research Institute Sant Pau (IIB-SantPau), Spain 3 Hospital de la Santa Creu i Sant Pau, Spain 4 Universitat Autònoma de Barcelona, Spain 5 Bellaterra, Spain 6 Universitat Autónoma de Barcelona, Spain 2
Targeted therapy represents one of the major challenges in Nanomedicine, with less than 5% of the antibody-targeted vehicles reaching target cells in most cases. In this regard, apart from displaying a specific ligand, it is critical to control biodistribution upon systemic administration by using vehicles of a suitable size and biological nature to avoid being captured in undesired organs, thus increasing their circulating times. In this context, we have developed a recombinant platform for the design of protein carriers that self-assemble as nanostructured materials. These proteins consist of different domains designed to target the cargo drug to a specific cell type and subcellular compartment, but also of architectural domains that promote self-assembling as nanoparticles of regular size. The combination of these features makes our de novo-designed vehicles fully biocompatible biomaterials with controllable physical and functional properties, stable in the bloodstream. We have developed nanoparticles targeted to specific cell types in different cancer models through recognition of cell surface markers and subsequent internalization, which confers specificity to the cargo antitumor drug. Such targeting minimizes drug side effects and increases its effectiveness in vivo. As an example, we describe the engineering of protein-only nanoparticles targeted to metastatic colorectal cancer. http://dx.doi.org/10.1016/j.nbt.2016.06.786
O4-5 Withdrawn
http://dx.doi.org/10.1016/j.nbt.2016.06.787
O4-6 Bacterial nanocellulose – A biotechnological product for biomedical applications Karolina Ludwicka ∗ , Przemysław Rytczak, Marek Kołodziejczyk, Edyta Gendaszewska-Darmach, Michał Chrzanowski, Katarzyna ˛ Kubiak, Marzena Jedrzejczak-Krzepkowska, Stanisław Bielecki Lodz University of Technology, Poland The interest in bacterial nanocellulose (BNC) application in medicine and tissues reconstruction has grown rapidly in the past decade. Different types of cellulosic implants are being analysed in accordance with the required properties. Native BNC, known as an excellent wet wound dressing, was developed at the Institute of Technical Biochemistry and already successfully applied in